Hearing On Natco Plea To Make Generic Version Of Roche, Pfizer Cancer Drugs Extended To March
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - An Indian patent office hearing on the closely watched application by Hyderabad, India-based Natco Pharma for a compulsory license to sell generic copies of Roche and Pfizer drugs to poor countries will continue next month, a spokesman for the patent office said
You may also be interested in...
Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
MUMBAI - An Indian generic drug maker cannot be halted from manufacturing and selling a generic version of Roche's locally patented lung cancer drug Tarceva (erlotinib) in what a spokesman for the Mumbai-based company said was a "landmark" ruling under the country's three-year-old patent regime
Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
MUMBAI - An Indian generic drug maker cannot be halted from manufacturing and selling a generic version of Roche's locally patented lung cancer drug Tarceva (erlotinib) in what a spokesman for the Mumbai-based company said was a "landmark" ruling under the country's three-year-old patent regime
India Patent Office to Make Key Decision on Export of Roche, Pfizer Cancer Drugs
NEW DELHI - India's patent office will hold hearings Feb. 28 and 29 to decide whether India's Natco Pharmaceuticals should be awarded the country's first compulsory license to make and export to Nepal generic cancer drugs patented locally by Roche and Pfizer